ReviewSurgical neurology international2022
A simplified overview of the World Health Organization classification of central nervous system tumors 2021.
Review in Surgical neurology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Dissecting the Dual Drug Candidates Against Glioblastoma and Oligodendroglioma Through Integrated Transcriptome Analysis and Virtual Screening.Cell biochemistry and biophysics · 2025Article
- PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.Scientific reports · 2024Article
- AKR1B1 Represses Glioma Cell Proliferation through p38 MAPK-Mediated Bcl-2/BAX/Caspase-3 Apoptotic Signaling Pathways.Current issues in molecular biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Building on the 2016 updated fourth edition and the work of consortium to inform molecular and practical approach to CNS tumor taxonomy, the major dramatic change occurs in 2021 fifth edition by advancing the role of molecular diagnostics in CNS tumor classification. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. Methods: The review was designed in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. Articles published in PubMed Central, Medline, and Embase databases till now were all searched. Only nonexperimental and nonanimal clinical studies were included in the study. Articles written only in the English language were considered. Results: All IDH mutant diffuse astrocytic tumors are considered in a single type "astrocytoma IDH mutant" and then graded as CNS WHO Grades 2-4. Pediatric-type diffuse gliomas are now classified as separate entity. Anatomical site is also taken into consideration to classify ependymoma. The "Desmoplastic myxoid tumor of the pineal region, SMARCB1 mutant" and "Atypical neurofibromatous neoplasm of unknown biological potential" are new tumor type added to pineal and neurofibroma group, respectively. Mesenchymal tumor is now termed as only solitary fibrous tumor. Adamantinomatous and papillary subtype of craniopharyngioma are now classified as distinct tumor type. The new term "Pituitary neuroendocrine tumor" has been coined for pituitary adenoma. Conclusion: The WHO CNS-5 introduces a new knowledge into the classification with progressive manner by introducing newly recognizing entities, by obsoleting tumor type, and by adjusting the taxonomic structure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.